314 related articles for article (PubMed ID: 21453735)
1. Ghrelin as a target for gastrointestinal motility disorders.
Greenwood-Van Meerveld B; Kriegsman M; Nelson R
Peptides; 2011 Nov; 32(11):2352-6. PubMed ID: 21453735
[TBL] [Abstract][Full Text] [Related]
2. Preclinical gastrointestinal prokinetic efficacy and endocrine effects of the ghrelin mimetic RM-131.
Van der Ploeg L; Laken H; Sharma S; Datta R; Halem H; Dong J; Touvay C; Teillot M; Noonan P; Tartaglia L; Stoner L; Henderson B; Gottesdiener K; Culler M
Life Sci; 2014 Jul; 109(1):20-9. PubMed ID: 24931905
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic applications of ghrelin agonists in the treatment of gastroparesis.
Shin A; Wo JM
Curr Gastroenterol Rep; 2015 Feb; 17(2):430. PubMed ID: 25702264
[TBL] [Abstract][Full Text] [Related]
4. Enhanced gastrointestinal motility with orally active ghrelin receptor agonists.
Charoenthongtrakul S; Giuliana D; Longo KA; Govek EK; Nolan A; Gagne S; Morgan K; Hixon J; Flynn N; Murphy BJ; Hernández AS; Li J; Tino JA; Gordon DA; DiStefano PS; Geddes BJ
J Pharmacol Exp Ther; 2009 Jun; 329(3):1178-86. PubMed ID: 19252061
[TBL] [Abstract][Full Text] [Related]
5. Ghrelin receptor agonists: a new class of prokinetic agents.
Neurogastroenterol Motil; 2010 Oct; 22(10):1043-4. PubMed ID: 20840719
[No Abstract] [Full Text] [Related]
6. Motilin, ghrelin and related neuropeptides as targets for the treatment of GI diseases.
Sanger GJ
Drug Discov Today; 2008 Mar; 13(5-6):234-9. PubMed ID: 18342799
[TBL] [Abstract][Full Text] [Related]
7. Ghrelin signaling in the gut, its physiological properties, and therapeutic potential.
Avau B; Carbone F; Tack J; Depoortere I
Neurogastroenterol Motil; 2013 Sep; 25(9):720-32. PubMed ID: 23910374
[TBL] [Abstract][Full Text] [Related]
8. Application of ghrelin to gastrointestinal diseases.
Venkova K; Greenwood-Van Meerveld B
Curr Opin Investig Drugs; 2008 Oct; 9(10):1103-7. PubMed ID: 18821473
[TBL] [Abstract][Full Text] [Related]
9. Motilin and ghrelin as prokinetic drug targets.
De Smet B; Mitselos A; Depoortere I
Pharmacol Ther; 2009 Aug; 123(2):207-23. PubMed ID: 19427331
[TBL] [Abstract][Full Text] [Related]
10. Randomised clinical trial: ghrelin agonist TZP-101 relieves gastroparesis associated with severe nausea and vomiting--randomised clinical study subset data.
Wo JM; Ejskjaer N; Hellström PM; Malik RA; Pezzullo JC; Shaughnessy L; Charlton P; Kosutic G; McCallum RW
Aliment Pharmacol Ther; 2011 Mar; 33(6):679-88. PubMed ID: 21214610
[TBL] [Abstract][Full Text] [Related]
11. Effect of the ghrelin receptor agonist TZP-101 on colonic transit in a rat model of postoperative ileus.
Fraser GL; Venkova K; Hoveyda HR; Thomas H; Greenwood-Van Meerveld B
Eur J Pharmacol; 2009 Feb; 604(1-3):132-7. PubMed ID: 19121631
[TBL] [Abstract][Full Text] [Related]
12. Potential of ghrelin as a therapeutic approach for gastrointestinal motility disorders.
Peeters TL
Curr Opin Pharmacol; 2006 Dec; 6(6):553-8. PubMed ID: 17011824
[TBL] [Abstract][Full Text] [Related]
13. Emerging treatments in Neurogastroenterology: relamorelin: a novel gastrocolokinetic synthetic ghrelin agonist.
Camilleri M; Acosta A
Neurogastroenterol Motil; 2015 Mar; 27(3):324-32. PubMed ID: 25545036
[TBL] [Abstract][Full Text] [Related]
14. Ghrelin and motilin receptors as drug targets for gastrointestinal disorders.
Sanger GJ; Furness JB
Nat Rev Gastroenterol Hepatol; 2016 Jan; 13(1):38-48. PubMed ID: 26392067
[TBL] [Abstract][Full Text] [Related]
15. Application of Pyridostigmine in Pediatric Gastrointestinal Motility Disorders: A Case Series.
Manini ML; Camilleri M; Grothe R; Di Lorenzo C
Paediatr Drugs; 2018 Apr; 20(2):173-180. PubMed ID: 29243034
[TBL] [Abstract][Full Text] [Related]
16. Gastroduodenal motility.
Tack J; Janssen P
Curr Opin Gastroenterol; 2010 Nov; 26(6):647-55. PubMed ID: 20838344
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of ipamorelin, a novel ghrelin mimetic, in a rodent model of postoperative ileus.
Venkova K; Mann W; Nelson R; Greenwood-Van Meerveld B
J Pharmacol Exp Ther; 2009 Jun; 329(3):1110-6. PubMed ID: 19289567
[TBL] [Abstract][Full Text] [Related]
18. Relamorelin and other ghrelin receptor agonists - future options for gastroparesis, functional dyspepsia and proton pump inhibitors-resistant non-erosive reflux disease.
Zatorski H; Mosinska P; Storr M; Fichna J
J Physiol Pharmacol; 2017 Dec; 68(6):797-805. PubMed ID: 29550791
[TBL] [Abstract][Full Text] [Related]
19. Ghrelin and Motilin Control Systems in GI Physiology and Therapeutics.
Sanger GJ; Broad J; Callaghan B; Furness JB
Handb Exp Pharmacol; 2017; 239():379-416. PubMed ID: 28035532
[TBL] [Abstract][Full Text] [Related]
20. Prokinetic effects of a new ghrelin receptor agonist TZP-101 in a rat model of postoperative ileus.
Venkova K; Fraser G; Hoveyda HR; Greenwood-Van Meerveld B
Dig Dis Sci; 2007 Sep; 52(9):2241-8. PubMed ID: 17436082
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
